Atlas Trials

Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers

Clinical trial NCT02515877 · COMPLETED

Trial details

NCT number
NCT02515877
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Cervical Cancer
Start date
2008-01-01
Primary completion
2013-04-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.